[{"id":"13166d68-2e61-4c72-92f1-fac024df7835","acronym":"SAFFRON","url":"https://clinicaltrials.gov/study/NCT05261399","created_at":"2022-03-02T17:52:38.442Z","updated_at":"2024-07-02T16:34:59.035Z","phase":"Phase 3","brief_title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","source_id_and_acronym":"NCT05261399 - SAFFRON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/26/2025","primary_completion_date":" 06/26/2025","study_txt":" Completion: 12/17/2026","study_completion_date":" 12/17/2026","last_update_posted":"2024-06-04"},{"id":"5b00d7b5-531c-43fe-b5d3-43c3fcc25ee7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02861898","created_at":"2021-01-18T14:02:57.277Z","updated_at":"2024-07-02T16:35:22.463Z","phase":"Phase 1/2","brief_title":"Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT02861898","lead_sponsor":"Northwell Health","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-24"},{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"},{"id":"52345c9c-541e-41a7-bdf5-45f77ff791e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02800486","created_at":"2021-01-18T13:44:19.209Z","updated_at":"2024-07-02T16:35:29.924Z","phase":"Phase 2","brief_title":"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA","source_id_and_acronym":"NCT02800486","lead_sponsor":"Northwell Health","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-11-08"},{"id":"ee75280d-fc90-465e-b0a5-f0b3469013da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05176665","created_at":"2022-01-04T13:53:37.122Z","updated_at":"2024-07-02T16:35:35.271Z","phase":"Phase 1/2","brief_title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","source_id_and_acronym":"NCT05176665","lead_sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression","tags":["EGFR • KRAS • BRAF • ALK • NRAS • ROS1 • FGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • MET amplification • EGFR amplification • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bafisontamab (EMB-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 08/04/2024","primary_completion_date":" 08/04/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-09-29"},{"id":"328e86c2-f909-458a-bfed-3477f5be5a6e","acronym":"NOTABLE-307","url":"https://clinicaltrials.gov/study/NCT05978050","created_at":"2023-08-07T14:08:43.635Z","updated_at":"2024-07-02T16:35:40.808Z","phase":"Phase 3","brief_title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","source_id_and_acronym":"NCT05978050 - NOTABLE-307","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 354","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-08-07"},{"id":"37f1e6c6-ed7e-486a-8292-5e853a74685b","acronym":"FAMOSO","url":"https://clinicaltrials.gov/study/NCT03001570","created_at":"2021-01-18T14:45:54.523Z","updated_at":"2024-07-02T16:35:44.566Z","phase":"Phase 2","brief_title":"Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District","source_id_and_acronym":"NCT03001570 - FAMOSO","lead_sponsor":"European Institute of Oncology","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-06-28"},{"id":"02bd8df0-2fe4-44b2-8867-3c5d0ec54fff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03888092","created_at":"2021-01-18T19:09:24.084Z","updated_at":"2024-07-02T16:35:52.781Z","phase":"Phase 1/2","brief_title":"Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification","source_id_and_acronym":"NCT03888092","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e larotinib (Z650)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2023-03-21"},{"id":"049acb0a-e716-4715-af42-f30f1499423c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05750290","created_at":"2023-03-01T15:02:17.647Z","updated_at":"2024-07-02T16:35:54.451Z","phase":"Phase 2","brief_title":"CKD-702 Plus Irinotecan in Gastric Cancer","source_id_and_acronym":"NCT05750290","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression • MET overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • CKD-702"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-03-01"},{"id":"9653dfea-b314-42ba-85bf-254d9e1c24d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415853","created_at":"2021-01-18T21:17:00.808Z","updated_at":"2024-07-02T16:36:05.477Z","phase":"Phase 3","brief_title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","source_id_and_acronym":"NCT04415853","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Teysuno (gimeracil/oteracil/tegafur) • larotinib (Z650)"],"overall_status":"Recruiting","enrollment":" Enrollment 416","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-08-15"},{"id":"8845b984-11a1-4717-8120-2e8e94f20777","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215925","created_at":"2022-02-05T18:27:53.813Z","updated_at":"2024-07-02T16:36:07.686Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression","source_id_and_acronym":"NCT05215925","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • pemetrexed • pimurutamab (HLX07)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 07/15/2023","primary_completion_date":" 07/15/2023","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2022-07-06"},{"id":"d5fb608c-cb96-4e4a-a0ee-288654bacebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447419","created_at":"2021-01-18T11:43:46.510Z","updated_at":"2024-07-02T16:36:08.665Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors","source_id_and_acronym":"NCT02447419","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 12/03/2014","start_date":" 12/03/2014","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2022-06-15"},{"id":"433b0ed5-b7bd-40ad-869d-1ed1411fc5f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316480","created_at":"2022-04-07T12:57:05.926Z","updated_at":"2024-07-02T16:36:13.809Z","phase":"Phase 2","brief_title":"Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms","source_id_and_acronym":"NCT05316480","lead_sponsor":"Fudan University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TheraCIM (nimotuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2022-04-07"},{"id":"5e2cc56d-4489-4e68-97aa-77f57a03e29e","acronym":"INSPIRE","url":"https://clinicaltrials.gov/study/NCT00982111","created_at":"2021-01-18T03:49:55.624Z","updated_at":"2024-07-02T16:36:18.612Z","phase":"Phase 3","brief_title":"First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin","source_id_and_acronym":"NCT00982111 - INSPIRE","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression • EGFR underexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression • EGFR underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Portrazza (necitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 633","initiation":"Initiation: 11/02/2009","start_date":" 11/02/2009","primary_txt":" Primary completion: 11/14/2012","primary_completion_date":" 11/14/2012","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2022-01-11"},{"id":"380a8863-daf3-4902-8a99-7907296c65b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03234712","created_at":"2021-01-18T15:59:05.637Z","updated_at":"2024-07-02T16:36:30.644Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)","source_id_and_acronym":"NCT03234712","lead_sponsor":"AbbVie","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e serclutamab talirine (ABBV-321)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 04/14/2021","primary_completion_date":" 04/14/2021","study_txt":" Completion: 04/14/2021","study_completion_date":" 04/14/2021","last_update_posted":"2021-05-06"},{"id":"1900325e-e2d0-44ec-828f-b3c2325be47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544997","created_at":"2021-01-18T12:18:45.719Z","updated_at":"2024-07-02T16:36:43.567Z","phase":"Phase 2","brief_title":"A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway","source_id_and_acronym":"NCT02544997","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2020-07-07"},{"id":"850ae188-410a-4e4d-a744-bf936a798cb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01855854","created_at":"2021-01-18T08:17:20.925Z","updated_at":"2024-07-02T16:36:58.374Z","phase":"Phase 2","brief_title":"Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH","source_id_and_acronym":"NCT01855854","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Conmana (icotinib)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 01/07/2016","study_completion_date":" 01/07/2016","last_update_posted":"2019-07-05"},{"id":"82595cd4-97b4-4f67-87c6-d473577783aa","acronym":"NIEGA","url":"https://clinicaltrials.gov/study/NCT03400592","created_at":"2021-01-18T16:46:56.575Z","updated_at":"2024-07-02T16:37:14.840Z","phase":"Phase 2","brief_title":"Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma","source_id_and_acronym":"NCT03400592 - NIEGA","lead_sponsor":"Peking University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • TheraCIM (nimotuzumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 55","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-01-17"},{"id":"f365a770-b2da-44e8-81a4-efc239287392","acronym":"","url":"https://clinicaltrials.gov/study/NCT01255657","created_at":"2021-01-18T05:03:48.133Z","updated_at":"2024-07-02T16:37:16.128Z","phase":"Phase 1","brief_title":"A Study of ABT-806 in Subjects With Advanced Solid Tumor Types","source_id_and_acronym":"NCT01255657","lead_sponsor":"AbbVie (prior sponsor, Abbott)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR wild-type • EGFR overexpression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR wild-type • EGFR overexpression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e depatuxizumab (ABT-806)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2017-11-21"}]